Showing 781-790 of 2293 results for "".
- FDA Gives Market Clearance for Muscle Stimulator to Reduce Snoring and Mild Obstructive Sleep Apneahttps://practicalneurology.com/news/fda-gives-market-clearance-for-muscle-stimulator-to-reduce-snoring-and-mild-obstructive-sleep-apnea/2469494/The Food and Drug Administration (FDA) authorized a prescription-only device (eXciteOSA; Signifier Medical Technologies, Silver Spring, MD) to reduce snoring and mild obstructive sleep apnea. The device is used when the individuals is awake to improve tongue muscle function. FDA a
- New Genetic Tests Available for Hereditary Ataxiashttps://practicalneurology.com/news/new-genetic-tests-available-for-hereditary-ataxias/2469486/Several genetic tests, including repeat-expansion analysis for spinocerebellar ataxia (SCA), Friedreich ataxia, and other common forms of hereditary ataxia have been newly made available by GeneDx (Gaithersberg, MD). The repeat-expansion analysis may be done concurrently with single nucleotide va
- Update on Migraine Incidence and Risk for Progression from Episodic to Chronic Migrainehttps://practicalneurology.com/news/update-on-migraine-incidence-of-migraine-and-risk-for-progression-from-episodic-to-chronic-migraine/2469439/At the Virtual Scottsdale Headache Symposium 2020, Richard Lipton, MD presented the latest data from epidemiology studies of migraine. Dr. Lipton noted that epidemiologic studies not only provide a conceptual model of the disease and approaches for better understanding but also help to assess and
- Posttraumatic Headache Management Update from Virtual Scottsdale Headache Symposium 2020https://practicalneurology.com/news/posttraumatic-headache-management-update-from-virtual-scottsdale-headache-symposium-2020/2469438/At the Virtual Scottsdale Headache Symposium 2020 held on November 21st, 2020, Dr. Juliana VanderPluym, MD, FAHS of the Mayo clinic reviewed current knowledge on management of posttraumatic headache, providing a step-by-step approach as follows below. 1. Posttraumatic headache is
- Teens with Epilepsy Are More Likely to Discuss Suicide Onlinehttps://practicalneurology.com/news/teens-with-epilepsy-are-more-likely-to-discuss-suicide-online/2469098/Results of a study presented at the American Epilepsy Society Annual Meeting December 6-10, 2019 in Baltimore, MD show that teens with epilepsy are more than twice as likely as adults with the condition to talk about suicide online. The data suggests that teens are concerned with the unknown aspe
- Women with Epilepsy Are Less Likely to Breastfeed Their Newbornshttps://practicalneurology.com/news/women-with-epilepsy-are-less-likely-to-breastfeed-their-newborns/2469096/Findings from 2 clinical studies presented at the American Epilepsy Society Annual Meeting, December 6-10 in Baltimore, MD show that women with epilepsy are less likely to breastfeed their newborns than new mothers without epilepsy. Support from neurologists and lactation consultants, however, ca
- Database of Eye-Tracking Movements Could Aid Diagnosis and Treatmenthttps://practicalneurology.com/news/database-of-eye-tracking-movements-could-aid-diagnosis-and-treatment/2468784/Eye-tracking technology (Brain Health EyeQ; RightEye, Bethesda, MD) that captures data on people’s eye movements has been used to produce a database of 1 billion data points from 100,000 individuals. Data includes eye tracking measures of alignment, object tracking, depth perception, and dy
- FDA Provides Expanded Clearance for Device to Treat Migraine in Childrenhttps://practicalneurology.com/news/fda-provides-expanded-clearance-for-device-to-treat-migraine-in-children/2468822/The Food and Drug Administration (FDA) has granted new marketing clearance for a device that provides acute and preventive treatment of migraine to include children 12 years of age and older. The technology (sTMS; eNeura, Inc., Baltimore, MD) is a non-invasive device that uses single-puls
- Cell Therapy for ALS Associated with Increased Survival at 5 Yearshttps://practicalneurology.com/news/cell-therapy-for-als-shows-promise-in-increasing-survival-at-five-years/2475217/Nine out of 10 people with amyotrophic lateral sclerosis (ALS) treated with NurOwn (autologous mesenchymal stem cells [MSC]–neurotrophic factors [NTF]; BrainStorm Cell Therapeutics, New York, NY) survived more than 5 years after symptom onset. These results from an analysis of survival data from
- New Technology May Help Differentiate Between Parkinsonismshttps://practicalneurology.com/news/new-technology-may-help-differentiate-between-parkinsonisms/2473819/A machine learning–based software tool (neuropacs; Gainesville, FL) analyzing 3T diffusion MRI scans was found to be effective in distinguishing between Parkinson disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP) in people with diagnosed movement disorder